Commercial-scale production of mRNA products is limited by their expense, complexity, and the high level of technical expertise required, which make them unsuitable for much of the world. A new ...
TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...
From vaccines to therapeutics, the emergence of mRNA as a versatile and potent biological tool across the healthcare landscape continues to demand new, innovative ways to scale mRNA manufacturing. To ...
A new study published on the preprint server bioRxiv in April 2020 reports the discovery of the structure of the cap created by the novel coronavirus on virally encoded mRNAs. The finding could help ...
The donation commemorates the launch of TriLink’s first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative products in one box at a competitive price.
TriLink’s CleanCap® AG (3’ OMe) CleanScript™ IVT Kit provides essential components for mRNA synthesis using co-transcriptional capping by in vitro transcription (IVT). The kit components are ...
Quantoom’s customers can now access TriLink’s CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results